The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe? and 2) Is treatment effective in improving cardiac function and clinical outcomes?

Condition or disease

Intervention/treatment

Acute Myocardial Infarction

Procedure: ASC isolation and implantation

Detailed Description:

The primary objectives of this study are to evaluate in patients recovering from acute myocardial infarction (< 8 days after the index infarction) both the safety profile of intramyocardial ASCs and the preliminary efficacy of ASCs therapy.

This will be an open-label, non-randomized patient sponsored multi-center study of ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The injection catheter will be used for delivery of the ASCs therapy.

An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation by a Catheter Delivery System and/or Intravenously In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction

This trial will study ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The injection catheter will be used for delivery of the ASCs therapy

Autologous ASCs therapy will be considered effective for post-myocardial infarction patients if there is an improvement in:

Absolute LVEF

Changes in LVEF from baseline to 6 months

MI size

Regional wall thickness and thickening in all segments

LV-end systolic volume (LV-ESV)

LV-end diastolic volume (LV-EDV)

Change in perfusion defect after revascularization to six months as measured by:

Echocardiography

Scintigraphy

Secondary Outcome Measures
:

Primary Safety Objective [ Time Frame: 6 months ]

The safety of adipose-derived stem cell injection will be evaluated by assessment of the frequency and nature of adverse events occurring during the study injection and up to the 6-month period following treatment.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years to 80 Years (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Males and Females between Age 18 and 80 years.

Defined acute myocardial infarction <8 days from screening

Left ventricular ejection fraction at screening of ≤ 50%, with 2 or more contiguous areas of severe wall motion abnormality on resting echocardiography.

Patients must have a minimum myocardial wall thickness of 5mm

Need or feasibility for re-vascularization has been ruled out by coronary angiogram or noninvasive stress testing.

Up to date on all age and gender appropriate cancer screening per American Cancer Society

Exclusion Criteria:

Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study

Life expectancy < 6 months due to concomitant illnesses.

NYHA CHF Class 4

Severe valvular or other non-ischemic myocardial disease.

Mechanical complications of the index acute myocardial infarction including but not limited to rupture of the mitral valve with resultant development of mitral regurgitation, rupture of the left ventricular free wall and rupture of the interventricular septum.

Active infectious disease and/or known to have tested positive for HIV, HTLV, HBV, HCV, CMV (IgM > IgG) and/or syphilis. If the panel includes antibodies to the HBV-cAg and HBV-sAg, then an expert will be consulted as to patient eligibility based on the patient's infectious status

Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results

Patients on chronic immunosuppressive transplant therapy

Systolic blood pressure (supine) ≤90 mmHg;

Resting heart rate > 100 bpm;

Active clinical infection within one week of enrollment.

Cerebrovascular accident within 6 months prior to study entry

Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.

History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years.